Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) provides access to the company’s official regulatory disclosures as a clinical-stage TechBio and biotechnology issuer. These documents offer detailed information about Recursion’s financial condition, governance, capital markets activity and key corporate events related to its Recursion OS platform and drug development programs.
Investors can review current reports on Form 8-K, where Recursion reports material events such as quarterly financial results, leadership transitions, collaboration milestones and equity issuances. Recent 8-K filings describe items including second and third quarter financial results, the appointment of a new Chief Executive Officer and President with the prior CEO becoming Chair of the Board, milestone payments from collaborations, and unregistered sales of equity securities connected to acquisitions and license arrangements.
Through its registration statements and prospectus supplements filed under its automatic shelf registration on Form S-3ASR, Recursion documents offerings and resale registrations for shares issued in connection with agreements such as a master license with Tempus AI, Inc. and a membership interest purchase agreement involving a joint venture for an ENPP1 program. These filings outline the number of shares involved, transaction structure and reliance on exemptions from registration for initial issuances.
Users of this page can also monitor filings related to corporate governance and stockholder matters, such as annual meeting results and advisory votes, as well as information about independent auditor ratification. Together with annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible through EDGAR, these filings form a comprehensive record of RXRX’s regulatory history.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of key filings. This helps readers quickly interpret lengthy documents such as 10-K and 10-Q reports, understand the implications of Form 8-K disclosures, and track any insider-related or equity issuance activity that may be relevant when evaluating Recursion Pharmaceuticals.
Recursion Pharmaceuticals director Christopher Gibson reported a planned share sale and related conversion. On January 20, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock at $0 per share pursuant to the Class B conversion feature. The same day, he sold 40,000 Class A shares at $4.47 per share under a Rule 10b5-1 trading plan adopted on May 12, 2025.
After these transactions, Gibson directly owned 913,839 shares of Class A Common Stock. He also reported additional indirect Class A holdings through entities he manages or serves as trustee, including 386,000 shares via LAHWRAN-3 LLC, 388,000 shares via LAHWRAN-4 LLC, and 50,000 shares via the Gibson Family Trust, as well as multiple outstanding stock options with various exercise prices and expirations.
Christopher C. Gibson has filed a Rule 144 notice to sell 40,000 shares of Class A stock through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate aggregate market value of $178,800 and an expected sale date of 01/20/2026. The filing reports that these 40,000 shares were acquired on 09/01/2016 as founders shares from the issuer as compensation. The notice lists 514,895,802 shares of this class outstanding. Over the prior three months, Gibson reported multiple sales of Class A shares, including 100,000 shares on 10/23/2025 for gross proceeds of $570,000 and separate 40,000‑share transactions on 11/04/2025, 11/19/2025, 12/04/2025, 12/19/2025, and 01/05/2026, with individual gross proceeds ranging from $166,400 to $208,400.
Recursion Pharmaceuticals, Inc. furnished an updated investor presentation dated January 12, 2026. The presentation will be used at the JP Morgan Healthcare Conference and in other investor meetings, giving an overview of the company and its strategy. It is attached as Exhibit 99.1 to this report and is provided under Regulation FD, meaning it is being shared to keep all investors equally informed. The materials are expressly treated as "furnished" rather than "filed," which limits their exposure to certain Exchange Act liabilities and affects how they may be incorporated by reference into other regulatory documents.
Recursion Pharmaceuticals’ CSO David Hallett filed a Form 3 disclosing his initial beneficial ownership in the company’s Class A common stock and equity awards as of 01/01/2026. He directly holds 287,928 shares of Class A common stock, plus restricted stock units (RSUs) covering 277,759 and 28,454 shares. These RSUs vest in equal quarterly installments from February 15, 2025 through November 15, 2028, and from May 15, 2025 through February 15, 2029, contingent on continued service.
Hallett also holds multiple stock options on Class A common shares, including options for 70,037 shares at
Recursion Pharmaceuticals director Blake Borgeson reported selling 220,000 shares of the company’s Class A common stock on January 6, 2026 at a price of $4.36 per share. After this transaction, he beneficially owned 6,649,863 shares of Class A common stock in direct ownership.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Borgeson adopted on August 31, 2025. Such plans are designed to allow insiders to sell shares according to a preset schedule or conditions, helping separate routine liquidity transactions from day-to-day market or company developments.
Recursion Pharmaceuticals director Christopher Gibson reported several share moves on January 5, 2026. He converted 60,000 shares of Class B Common Stock into 60,000 shares of Class A Common Stock at a stated price of $0, then sold 40,000 Class A shares at $4.25 per share and made a gift of 20,000 Class A shares. After these transactions, he directly held 913,839 shares of Class A Common Stock.
The filing also shows he directly holds 4,663,334 shares of Class B Common Stock, each convertible into one Class A share, and additional Class B holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust. Multiple stock options to buy Class A shares remain outstanding with exercise prices ranging from $2.48 to $11.40 and expirations between 2030 and 2035. The conversion, sale, and gift were made under a Rule 10b5-1 trading plan adopted on May 12, 2025.
Recursion Pharmaceuticals director Dean Y. Li received a new equity grant. On 01/02/2026, he was awarded 2,381 shares of Class A Common Stock at a price of $0. The filing states these shares were issued under the company’s Outside Director Compensation Policy, meaning they represent routine board compensation rather than an open-market purchase. After this grant, Li directly beneficially owned 1,240,909 Class A shares, in addition to indirect holdings through the Dean Y. Li Revocable Trust, the Dean Y. Li GRAT, and the Dean Y. Li 2021 Family Trust.
Recursion Pharmaceuticals, Inc. reported an insider equity transaction by its Chief Financial Officer on 12/15/2025. The filing shows that 7,057 shares of Class A common stock were disposed of at $4.33 per share. According to the footnote, these shares were withheld by the company to cover tax withholding and remittance obligations related to the net settlement of restricted stock units, rather than an open-market sale.
After this tax withholding event, the reporting person beneficially owned 782,933 shares of Class A common stock directly. The transaction is characterized with code "F," which typically denotes payment of tax liability by withholding securities incident to vesting of equity awards.
Recursion Pharmaceuticals, Inc. (RXRX) Chief Financial Officer reported a routine share withholding related to equity compensation. On 11/25/2025, 2,271 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $4.03 per share. This code indicates shares were withheld by the company to cover tax withholding and remittance obligations arising from the net settlement of restricted stock units.
Following this transaction, the reporting officer beneficially owns 789,990 shares of Class A common stock in direct ownership. No new derivative securities transactions were reported in this filing.
Recursion Pharmaceuticals, Inc. filed a prospectus supplement to register for resale 7,088,742 Tempus Shares of its Class A common stock. These shares were issued to Tempus AI, Inc. as payment of annual license fees under a Master Agreement between the two companies.
The resale registration uses Recursion’s automatic shelf registration statement on Form S-3ASR and provides Tempus the ability to sell the shares in the public market. The company also filed a legal opinion from Wilson Sonsini Goodrich & Rosati, P.C. confirming the validity of these shares.